Condition
Idiopathic Inflammatory Myopathies(IIM)
Total Trials
3
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Early P 1 (2)
P 1 (1)
Trial Status
Recruiting2
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07527936Early Phase 1Not Yet Recruiting
A Study of BEN301 Injection in theTreatment of Autoimmune Diseases
NCT07331272Phase 1Recruiting
A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)
NCT07174843Early Phase 1RecruitingPrimary
An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
Showing all 3 trials